Related Experiment Video

Updated: Aug 19, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Antivascular endothelial growth factor monoclonal antibody therapy: a promising paradigm in colorectal cancer

Paula J Franson1, Denise V Lapka

  • 1Rush University Medical Center, Chicago, IL, USA.

Clinical Journal of Oncology Nursing
|March 9, 2005
PubMed

Insights

Bevacizumab, a targeted therapy for colorectal cancer, significantly extends survival by inhibiting vascular endothelial growth factor (VEGF). This anti-VEGF antibody offers a promising treatment option for metastatic colorectal cancer patients.

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Angiogenesis, driven by vascular endothelial growth factor (VEGF), is crucial for tumor growth and development.
  • VEGF is a key target for colorectal cancer (CRC) therapy due to its proangiogenic role.
  • Bevacizumab is a monoclonal antibody designed to neutralize VEGF.

Purpose of the Study:

  • To review the role of VEGF in tumorigenesis.
  • To summarize clinical data on bevacizumab for metastatic colorectal cancer treatment.

Main Methods:

  • Review of preclinical and clinical studies (Phase I, II, and III) of bevacizumab.
  • Analysis of data on bevacizumab in combination with 5-fluorouracil-based chemotherapy.

Main Results:

  • Bevacizumab has shown promising activity and good tolerability in preclinical and early-phase studies.
  • Phase III trials demonstrated a survival benefit of approximately five months for patients receiving bevacizumab plus chemotherapy compared to chemotherapy alone.
  • The U.S. Food and Drug Administration approved bevacizumab for first-line metastatic colorectal cancer therapy.

Conclusions:

  • Bevacizumab is an effective targeted therapy for metastatic colorectal cancer.
  • Inhibition of VEGF with bevacizumab offers a survival advantage in combination chemotherapy regimens.
  • Bevacizumab represents a significant advancement in the treatment of metastatic colorectal cancer.

More Related Videos

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...